Sionna Therapeutics (NASDAQ:SION) Announces Quarterly Earnings Results

Sionna Therapeutics (NASDAQ:SION) released its quarterly earnings data on Monday. The company reported ($0.46) earnings per share for the quarter, FiscalAI reports.

Sionna Therapeutics Price Performance

Shares of SION opened at $36.54 on Monday. The company has a 50-day simple moving average of $39.78 and a two-hundred day simple moving average of $35.13. The firm has a market capitalization of $1.63 billion and a PE ratio of -7.50. Sionna Therapeutics has a one year low of $7.26 and a one year high of $45.00.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SION. BTIG Research reissued a “buy” rating and set a $58.00 price target on shares of Sionna Therapeutics in a research report on Wednesday, January 14th. Royal Bank Of Canada reaffirmed an “underperform” rating and set a $24.00 price objective on shares of Sionna Therapeutics in a research note on Monday, December 1st. Wall Street Zen raised Sionna Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. Weiss Ratings restated a “sell (e+)” rating on shares of Sionna Therapeutics in a report on Monday, December 29th. Finally, Citigroup initiated coverage on Sionna Therapeutics in a research report on Tuesday, February 24th. They set an “outperform” rating for the company. Two research analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $47.63.

Insider Transactions at Sionna Therapeutics

In other news, major shareholder Tpg Gp A, Llc sold 250,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $40.00, for a total value of $10,000,000.00. Following the completion of the transaction, the insider owned 6,494,962 shares in the company, valued at $259,798,480. This trade represents a 3.71% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Orbimed Advisors Llc sold 33,356 shares of the company’s stock in a transaction on Wednesday, December 24th. The stock was sold at an average price of $44.55, for a total value of $1,486,009.80. Following the completion of the sale, the director directly owned 3,561,655 shares in the company, valued at approximately $158,671,730.25. The trade was a 0.93% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 382,368 shares of company stock valued at $15,898,607. Corporate insiders own 3.90% of the company’s stock.

Institutional Investors Weigh In On Sionna Therapeutics

Several hedge funds have recently bought and sold shares of SION. Prudential Financial Inc. grew its stake in shares of Sionna Therapeutics by 114.6% in the second quarter. Prudential Financial Inc. now owns 135,185 shares of the company’s stock worth $2,345,000 after acquiring an additional 72,185 shares during the last quarter. Braidwell LP bought a new position in Sionna Therapeutics in the 2nd quarter worth about $18,770,000. Bosun Asset Management LLC purchased a new stake in Sionna Therapeutics during the 2nd quarter valued at about $295,000. JPMorgan Chase & Co. increased its stake in Sionna Therapeutics by 2.4% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,221,188 shares of the company’s stock valued at $38,538,000 after purchasing an additional 51,589 shares in the last quarter. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in Sionna Therapeutics during the 2nd quarter valued at about $45,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.